Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HLX 23

Next Previous
Drug Profile

HLX 23

Alternative Names: HLX-23; Recombinant anti-CD73 fully humanised monoclonal antibody injection

Latest Information Update: 20 Jun 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Henlix Biotech
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 20 Jun 2023 Discontinued - Preclinical for Solid tumours in Taiwan (IV) (before June 2023) (Shanghai Henlius Biotech Pipeline, June 2023)
  • 13 Jan 2023 Shanghai Henlius Biotech withdraws a phase I trial in solid tumours (Late-stage disease, Metastatic disease, Second-line therapy, Monotherapy) in USA (IV) prior to enrolment and the result of the sponsor's need to reevaluate the study design and to make needed vendor realignments (NCT04797468)
  • 01 Jun 2021 US FDA approves IND application in Solid tumours

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top